Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences

Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences

Item

http://www.wikidata.org/entity/Q33710994

Q33710994

about

michGranulopoiesis-stimulating factors for preventing infections after autologous peripheral stem cell transplantation for lymphoma and multiple myeloma in adults First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies Granulopoiesis-stimulating factors for preventing infections after autologous peripheral stem cell transplantation for lymphoma and multiple myeloma in adults Novel agents for multiple myeloma to overcome resistance in phase III clinical trials Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvement Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737 Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma.Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy Lenalidomide after stem-cell transplantation for multiple myeloma Curing myeloma at last: defining criteria and providing the evidence.A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival.Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma Maintenance therapy with immunomodulatory drugs after autologous stem cell transplantation in patients with multiple myeloma: a meta-analysis of randomized controlled trials.Complete response after autologous stem cell transplant in multiple myeloma Approach to the treatment of multiple myeloma: a clash of philosophies.Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3 Haematopoietic stem cell transplantation as first-line treatment in myeloma: a global perspective of current concepts and future possibilities Oncolytic virotherapy for hematological malignancies.International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.IMWG consensus on maintenance therapy in multiple myeloma.European perspective on multiple myeloma treatment strategies: update following recent congresses Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT.Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.Impact of tandem autologous stem cell transplantation and response to transplant in the outcome of multiple myeloma.Stem cell transplantation for multiple myeloma: current and future status Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1 Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology Total marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma.Pursuing the curative blueprint for early myeloma.Posttransplant maintenance therapy in multiple myeloma: the changing landscape.Multiple myeloma treatment strategies with novel agents in 2011: a European perspective Continuous treatment in multiple myeloma - ready for prime time?Evolving therapeutic paradigms for multiple myeloma: back to the future.Emerging biological insights and novel treatment strategies in multiple myeloma.Understanding the molecular biology of myeloma and its therapeutic implications.Current approaches for the treatment of multiple myeloma.Diagnosis and therapy of multiple myeloma.

P2860

Q24186266-2D04F4CB-8372-4D50-A2BB-F2AA44DD7980 Q24197999-6C8B123F-E784-42E7-9F82-112824FB05FE Q24200850-F819F3FF-01C2-44FB-827A-6BD9C60ABD63 Q26822754-20607E49-6299-4021-A442-264722466771 Q27011865-18D2B38F-CE6B-4F9C-8C99-96A1734FA655 Q28542684-45C32F29-D7F5-4498-AFFA-C1B5FB9B6D76 Q30249513-7652E5E3-A275-4ECC-A51D-8471D2431E6E Q33401759-7F7388BF-27C0-478F-97A5-A29EBC03CE4A Q34122646-B814813A-A015-431F-9564-C2295E558254 Q34273726-D245B26D-4CD8-408B-A2CB-B117B12F25D5 Q34508313-89BD2EFE-FC8A-4FAC-A5C7-51B2D7A5CAD3 Q34634446-89412B97-9EDD-4184-AC72-4B34FFF20B82 Q34647698-7E5E292C-C449-4F91-97A7-49F1581C4CC8 Q34694749-5ABFBD57-08D5-4C56-ADC0-E0D779327832 Q34973992-CD453754-1BD5-4CC3-96A0-3E97A6D067CD Q35000475-1AE7BA0C-9C95-43CA-8757-B4A4F8988A19 Q35230189-BE1FBED8-0B1F-412C-8EF3-D0F2A351280D Q35266125-E142E83D-5FA9-42D9-A950-92943042C698 Q35569350-A583525E-250A-4C6B-9CF9-C7E3A1375045 Q35692095-855D2C1D-526A-4789-B895-2A44E9C39014 Q35802414-F060F1B3-7406-44AF-BF08-B620AFFFED74 Q35876966-B93BD7DB-6320-4D91-95F4-E153623D4AF3 Q35989943-942BD12F-7455-413E-9106-9A6D537D3DBE Q36031316-D6FFB051-9058-4A28-9C51-33FDC2D90C93 Q36162690-648BB161-6E04-4E8B-B25A-38CAC74DB8C4 Q36498366-F0EF622E-F193-4B72-AD00-2E8BF9B45D9E Q36541807-ECAD2226-6B64-4483-9ED6-1AD305DFACB5 Q36852229-0467B2EE-F315-401A-81B6-26926D44B47D Q36915777-B36ECDED-B729-413B-AD7E-91E57D5623AB Q36963203-8DC954CE-A872-4276-8614-46F10BC27752 Q37030249-D7BD0CBE-6608-4136-AA34-68E0EF9B9AC4 Q37046979-C2431241-1968-4461-AB6B-E126A9CA67D6 Q37737800-F8EDB492-DB58-4591-9E8E-2EA9C3B9449E Q37858327-72809206-193E-4F67-ACF3-A44E08CE8501 Q37936111-4D38E06F-2C34-4FEC-A111-1397E3BA0BCE Q38033590-39E525A1-DB2C-4A52-A2FF-F6300F366FE3 Q38037600-0595B0B3-7C68-4E92-8D64-0AB512C30E58 Q38065305-AF8D929E-2023-472B-9556-458F0576B905 Q38087939-70169C12-52EB-483B-98F7-90E1F39ACD74 Q38107482-94763547-02C9-459D-A178-0F235CA02AE2

P2860

Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences

Item

http://www.wikidata.org/entity/Q33710994

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu